Study finds iron levels not predictive of survival for form of blood cancer
Monday, May 11, 2009 - 14:42
in Health & Medicine
Rochester, Minn. - May 11, 2009 - Iron chelating drugs have been heavily promoted for use in patients with primary myelofibrosis (PMF), a form of blood cancer often treated with blood transfusion. These drugs, however, which withhold available iron in the body, are highly expensive and potentially toxic.